The four assets, and how each one actually transfers
A telehealth business is four assets wearing one P&L, and they transfer very differently. The patient base is not a list; it is a retention curve that re-decides every month, so what you are buying is the cohort behavior (how many of last January's starts still pay today), not the count of names in the CRM. The clinical network is often a set of personal arrangements: a medical director who knows the seller, collaborating physicians, and in corporate-practice-of-medicine states a clinician-owned professional entity bound to the business by management agreements that commonly need consent, and sometimes full re-papering, to survive a sale.
The supply chain is contracts with counterparties: pharmacy relationships, per-fill pricing, and wholesale terms frequently carry change-of-control or assignment clauses, which means the economics on the listing may be economics the seller negotiated and you have to re-earn. And the compliance surface is the least transferable of all: certifications are typically tied to the entity and its websites and get re-reviewed when ownership changes, ad accounts carry history that does not simply hand over, and clinician licenses belong to clinicians, not to the company you are buying.
The one-question stress test: if the seller walks away on day one and the medical director resigns on day thirty, what did you actually buy? Whatever survives that scenario is the asset. Everything else was the seller.
The diligence the listing won't do for you
Ask for cohort tables, not blended churn: monthly retention by start cohort for the trailing periods, which is the only view that shows whether the curve is holding, improving, or being papered over by acquisition spend. Ask for the cost stack in writing: the actual per-fill medication economics, platform and software fees, clinician compensation model, and payment processing terms, because a margin built on a handshake price is a margin you do not own. Ask for the regulatory file: state registrations, the professional-entity structure and its management agreements, complaint and chargeback history, and any correspondence with certification bodies or boards.
Then map key-person dependency honestly. If the seller is also the prescribing clinician, the audience, or the face of the brand (creator-led programs especially), the growth engine may be the one asset that cannot be in the deal. None of this is exotic diligence; it is the ordinary homework the turnkey framing is designed to make feel unnecessary.
Pricing it against the build path
Whatever valuation language the broker uses, your ceiling price has a clean external benchmark: what it costs to build the same capability today. The historically expensive parts of telehealth (a fifty-state clinical network, pharmacy supply, the compliance scaffolding, the storefront technology) are now rentable as a platform layer, which means a seller's goodwill number is often asking you to pay a premium for infrastructure that has become a subscription. Price the durable pieces: proven cohort retention, contracts that survive assignment, an audience channel you could not cheaply rebuild. Discount the rest.
Run the comparison explicitly: model the acquisition (price, plus the re-papering, plus the parts that will not transfer and must be rebuilt anyway) against a fresh launch with the same audience and program menu, and treat both models as illustrations of your assumptions rather than predictions. If the deal only wins because the model assumes the listing's retention holds under new ownership, you have found the assumption to attack hardest.
When buying beats building, honestly
Buying wins when the deal contains something genuinely slow or expensive to replicate: a real licensed and credentialed footprint, cohorts with demonstrated multi-month retention, durable supply terms that survive the sale, or an owned audience in a niche you could not enter cold. Buying loses when the goodwill is mostly infrastructure you can rent, growth is entirely paid acquisition (which transfers perfectly and proves nothing), or the value walks out the door with the seller.
EmbedCare's role in this decision is the benchmark: the platform is the build path priced in known terms, with the clinical network, pharmacy supply, compliance scaffolding, and storefront operated behind your brand, flat product rates fixed in a signed partner agreement, and a self-serve Launch tier starting at $495/mo. Price any acquisition against that path, and either answer becomes a decision instead of a hope. The earnings calculator will run the build-side model, framed as a model.
Frequently asked
- Is buying an existing telehealth business a good idea?
- It depends entirely on what transfers. The strong version of the deal includes proven cohort retention, contracts that survive assignment, and an audience you could not cheaply build; the weak version is paid-acquisition revenue plus infrastructure you could rent as a platform subscription, priced as goodwill. Run the diligence frame (cohort tables, cost stack in writing, the regulatory file, key-person dependency) before you believe either version.
- How are telehealth businesses valued?
- Brokers typically talk in multiples of seller's discretionary earnings or revenue, but published multiples for this niche are noisy and self-reported, so we won't quote numbers. The honest anchors are internal: the durability of the retention curve, which contracts and relationships actually survive the sale, and what building the same capability would cost on a platform today. That last one is your ceiling, whatever the listing says.
- What should I ask for when buying a telehealth company?
- Cohort retention tables by start month rather than blended churn; the complete per-patient cost stack in writing, including medication economics and platform fees; the professional-entity structure and management agreements in corporate-practice-of-medicine states; assignment and change-of-control language in pharmacy and vendor contracts; complaint, refund, and chargeback history; and a plain answer to who the medical director and the audience actually are once the seller leaves.
- Do licenses and certifications transfer when you buy a telehealth business?
- Often not automatically, and the details decide the timeline. Clinician licenses belong to the clinicians, so the question is whether the network stays. Certifications are commonly tied to the entity and its websites and get re-reviewed on ownership changes. State registrations, pharmacy contracts, and ad accounts each have their own transfer rules, and an asset sale versus an entity sale changes the answer for all of them. Build the transfer map before closing, not after.
Want pricing for your program, and the Rx menu that goes with this?
The partner overview in one email; a human follows up with pricing scoped to your program.